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demand shows how consumers feel about a particular
product and its substitutes, thus having direct economical
impact on consumption.
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OBJECTIVE: To investigate the incremental cost-effec-
tiveness of ganciclovir relative to acyclovir in preventing
cytomegalovirus disease (CMV) after liver transplanta-
tion, using Bayesian methods. METHODS: Analysis was
based on 134 patients in a randomized clinical trial com-
paring oral acyclovir (ACV) to intravenous ganciclovir
followed by oral acyclovir (GCV). Probability of CMV,
ICU and non-ICU days and total billed charges were
modeled as interdependent binomial, poison and log-
transformed linear regressions of recipient, donor and
surgery covariates using Markov Chain Monte Carlo
(MCMC) with non-informative priors. RESULTS: The
posterior median (PM) attributable risk reduction for
CMV ranged from 16% (95% posterior range (PR): 5%–
22%) when both recipients and donors are previously ex-
posed to cytomegalovirus (R/D) to 29% (95%PR:
7%–43%) when recipients are not exposed, but donors
are (R/D). For average patients, CMV infection yields
a PM 3.5 ICU day increase (95%PR: 2.3–5.0) and a PM
1.9 non-ICU day increase (95%PR: .2–3.7). The associa-
tion of additional days with total charges is non-linear.
On average, increasing ICU-days from 4 to 5 yields a PM
increase in total billed charges of $3,692 (95%PR: $2,501–
$4,955), and increasing non-ICU days from 12 to 13
yields a PM increase of $1,311 (95%PR: $610–$2,052).
Independent of the impact on days, CMV yields a PM
$17,638 charge increase (95%PR $5,539–$31,220). The
average incremental cost-effectiveness for the study sample
is a 14.8% risk reduction and $12,048 savings. 73.1%
percent of the probability mass of the incremental cost-
effectiveness distribution lies in the “dominant quadrant”
(GCV reduces infections and total charges). For R/D
cases, GCV dominates ACV 93.5% of the time, and aver-
age incremental cost-effectiveness is a 27.1% risk reduc-
tion and $19,545 savings. CONCLUSION: The study
demonstrates cost-effectiveness of GCV relative to ACV
in prevention of CMV post transplant. The model explic-
itly associates covariates and treatment with cost-effec-
tiveness, reflecting uncertainty using a Bayesian frame-
work.
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Antibiotic misuse is a growing national concern. Sinusitis
is the leading indication for adult antibiotic outpatient
prescriptions. Physician prescribing behavior was care-
fully reviewed in treating sinusitis with approved antibi-
otic agents. METHODS: All subjects with pharmacy
claims for acute sinusitis (ICD9-CM code of 461) in the
year 1997 to 1998 from a 932,000 enrollee Midwest in-
surance company were included in the study. A logistic
regression model (N  12,765) was used to identify fac-
tors affecting the choice of antibiotic, with clarithromy-
cin prescription coded as “1” and any other antibiotic
prescription (amoxicillin, amoxicillin-clavulanate, eryth-
romycin, erythromycinsulfisox, loracarbef, cephalosporin,
azithromycin) coded as “0”. The independent variables
included in the model were age category (12–20, 21–40,
41–65, and 65 years or older), gender, success rate for
each antibiotic, incidence of second, third or fourth epi-
sode within the year, pre and intra-episode severity. RE-
SULTS: The mean age of subjects was 29.7 ( 17.8)
years. The prevalence rate of sinusitis was 12 cases per
1000, of which, 13 percent had two or more episodes of
sinusitis within a year. Patients with two episodes were
19 times more likely to get initial treatment with clarithro-
mycin than patients in first episode. The odds of treat-
ment initiation with clarithromycin were 27 percent
higher when age increased by one categorical unit. The
odds of treatment initiation with clarithromycin was 18
percent higher in women compared to men. CONCLU-
SION: The results indicated that clarithromycin is used
more often for treating sinusitis in patients who have
multiple episodes. Generalization of this analysis needs to
be confirmed using data from multiple managed care plans.
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OBJECTIVES: The clinical course of chronic bronchitis is
characterized by acute exacerbations (AECB), during which
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patients experience worsening of symptoms including in-
creased cough and sputum production and shortness of
breath. The present multicentre study was carried out in
an ambulatory setting in Germany, to compare and con-
trast the QoL of individuals with chronic bronchitis during
the stable phase and acute exacerbations. METHODS: Pa-
tients were admitted to the study if they developed an
acute episode of chronic bronchitis. Two hundred and
thirty five patients completed the St. George Hospital Res-
piratory Questionnaire (SGRQ) and the Nottingham Health
Profile (NHP) at study entry and during a stable phase sev-
eral months later. The study ran from October 1, 1996 un-
til March 31, 1998. RESULTS: The following hypotheses
will be tested:
• QOL will be poorer in men, in those with increasing
number of exacerbations in the previous 12 months
and in those who smoke and have exposure to other
risk and clinical factors.
• The more severe the AECB, and the more severe the
underlying condition, the poorer will be the quality
of life at the time of the AECB and the greater will be
the reduction in QOL from baseline.
• In general, the greater the number of potential prog-
nostic factors the poorer the QOL will be at the time
of both the AE and at ‘baseline’.
• Although the NHP and the SGRQ will show similar
trends the SGRQ will be expected to be more sensi-
tive: it will show a greater change from baseline to
AECB and will show a stronger association with clin-
ical factors such as the severity of the condition.
CONCLUSION: On the basis of the results of the analy-
ses, conclusions will be drawn which will clarify the effect
of exacerbations on the quality of life of people with CB.
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OBJECTIVES: To investigate cost-effectiveness and in-
cremental cost-effectiveness ratio for basic and immuno-
tropic therapy. METHODS: In cost-effectiveness analysis
the costs consist of expenditures for in-patient, out-
patient and emergency care, pharmacotherapy and indi-
rect expenditures for temporary invalidity of parents and
non-payment taxes. During one year prospective ran-
domized simultaneous investigation was conducted in
150 children with middle severe asthma. The patients of
the first group (50 children) were treated by sodium cro-
moglycate as basic therapy, the second group (50 chil-
dren), sodium nedocromil, the third group (50 children),
combination of sodium nedocromil and broncho-munal.
Cost-effectiveness criterion included the cost of one
asymptomatic day per year with determination clinico-
immunological indices. RESULTS: Investigation revealed
that the clinical effectiveness of basic and immunotropic
therapy were different. The most prolonged (341,4 
1,96 days) asymptomatic period was defined in patients
of the third group, the cost of one asymptomatic day was
the lowest (8,97  0,21 rubles) per year. Comparing
with the first group in the second one expenditures were
increased insignificantly (6,73 rubles) and effectiveness
was increased considerably (24,3 days), incremental
cost-effectiveness ratio was low (C/E  0,277). In-
verse dynamics of total expenditures (1990,17 rubles)
and increasing of treatment effectiveness (8,6 days, P 
0,01) was defined including broncho-munal therapy, in-
cremental cost-effectiveness ratio was 231,42. CON-
CLUSION: Increasing treatment effectiveness and de-
creasing expenditures was determined including broncho-
munal in complex therapy. Correlation between cost
and treatment effectiveness was rational in complex ther-
apy of child’s asthma with broncho-munal and sodium
nedocromil.
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OBJECTIVE: To test the hypothesis that health-related
quality of life is reduced as likelihood of asthma in-
creases. METHODS: The EuroQol EQ-5D questionnaire
and a modified European Community Respiratory Health
Survey questionnaire were administered by post to the
patients of two general practices in South Manchester,
UK in 1999. EQ-5D asks respondents to rate their func-
tion in 5 domains and also their overall health state on a
visual analogue scale (VAS). Valuations obtained from
the general public enable conversion of the domain re-
sponses to a single index value. RESULTS: More than
half (56%) of the subjects returned completed question-
naires. Significant trends towards lower health-related
quality of life (HRQoL) were seen with increasing age
and lower educational achievement. HRQoL was also
significantly worse in those considered ‘likely to have
asthma’ on the basis of their responses to the respiratory
symptom questionnaire. Mean domain derived score for
those likely to have asthma was 0.59 compared to 0.82
for those unlikely to be asthmatic (t  17.33 P 
0.0001). Mean self-reported VAS health states were 61.6
and 78.1 respectively (t  21.07 P  0.0001). Amongst
those considered ‘likely to have asthma,’ there was no
significant difference in HRQoL between those with and
without a confirmed diagnosis. CONCLUSION: The
EQ-5D has discriminant validity in the context of respi-
ratory disease. Use of the questionnaire in a postal survey
is an efficient way of obtaining HRQoL data from a pop-
ulation. It may be a useful tool to establish baseline
HRQoL data and subsequently to assess the impact of in-
